IQ-AI Limited (GB:IQAI) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
IQ-AI Limited has shared promising results from their Phase 1 clinical trial of oral gallium maltolate for treating glioblastoma, with some patients showing no disease progression for over six months. The company is preparing for a Phase 2 trial estimated at $2-2.5 million, aiming to start in 2025 with more extensive patient enrollment and a focus on overall survival. IQ-AI holds exclusive rights for commercialization and is looking to strengthen its IP position while considering future partnerships post-Phase 2 success.
For further insights into GB:IQAI stock, check out TipRanks’ Stock Analysis page.
